Hyperfine Announces Ten Abstracts at RSNA, Highlighting the Expanding Utility and Potential of Portable MR Brain Imaging in Diverse Clinical and Research Settings
Hyperfine (Nasdaq: HYPR) announced that ten scientific abstracts featuring ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. This represents the company's largest number of RSNA presentations to date, demonstrating growing interest in the Swoop® Portable MR Imaging® System. The abstracts cover diverse applications including emergency department workflow, neuro ICU implementation, intracerebral hemorrhage monitoring, acute ischemic stroke detection, and advanced imaging techniques for multiple sclerosis. The presentations highlight the system's versatility across multiple care settings and its potential to transform brain imaging and enhance patient care.
Hyperfine (Nasdaq: HYPR) ha annunciato che dieci riassunti scientifici focalizzati sull'imaging a ultra-basso campo saranno presentati al Meeting Annuale della Società Radiologica del Nord America (RSNA) 2024 a Chicago. Questo rappresenta il numero più elevato di presentazioni RSNA da parte dell'azienda fino ad oggi, dimostrando un crescente interesse per il Swoop® Portable MR Imaging® System. I riassunti coprono diverse applicazioni, tra cui il flusso di lavoro nei pronto soccorso, l'implementazione in unità di terapia intensiva neurologica, il monitoraggio dell'emorragia intracerebrale, la rilevazione dell'ictus ischemico acuto e tecniche di imaging avanzate per la sclerosi multipla. Le presentazioni evidenziano la versatilità del sistema in vari contesti clinici e il suo potenziale nel trasformare l'imaging cerebrale e migliorare la cura dei pazienti.
Hyperfine (Nasdaq: HYPR) anunció que diez resúmenes científicos sobre imagenología de ultra-bajo campo se presentarán en la Reunión Anual de la Sociedad Radiológica de América del Norte (RSNA) 2024 en Chicago. Esto representa la mayor cantidad de presentaciones de la RSNA por parte de la empresa hasta la fecha, demostrando un creciente interés en el Swoop® Portable MR Imaging® System. Los resúmenes abarcan diversas aplicaciones, incluyendo el flujo de trabajo en departamentos de emergencia, la implementación en unidades de cuidados intensivos neurológicos, el monitoreo de hemorragias intracerebrales, la detección de accidentes cerebrovasculares isquémicos agudos y técnicas avanzadas de imagen para la esclerosis múltiple. Las presentaciones subrayan la versatilidad del sistema en múltiples entornos de atención y su potencial para transformar la imagenología cerebral y mejorar la atención al paciente.
Hyperfine (Nasdaq: HYPR)는 초저장 필드 이미징을 다룬 10개의 과학 초록이 2024년 북미 방사선학회(RSNA) 연례 회의에서 시카고에서 발표될 것이라고 발표했습니다. 이는 회사가 지금까지 진행한 RSNA 발표 중 최대 수량으로, Swoop® Portable MR Imaging® System에 대한 관심이 증가하고 있음을 보여줍니다. 초록은 응급실 작업 흐름, 신경학적 ICU 구현, 두개내 출혈 모니터링, 급성 허혈성 뇌졸중 탐지 및 다발성 경화증에 대한 고급 이미징 기술을 포함한 다양한 응용 프로그램을 다룹니다. 발표는 여러 치료 환경에서의 시스템의 다재다능성을 강조하고 뇌 이미징을 혁신하고 환자 치료를 향상시킬 수 있는 잠재력을 보여줍니다.
Hyperfine (Nasdaq: HYPR) a annoncé que dix résumés scientifiques concernant l'imagerie à ultra-basse fréquence seront présentés lors de la Réunion Annuelle de la Société Radiologique d'Amérique du Nord (RSNA) 2024 à Chicago. Cela représente le plus grand nombre de présentations RSNA de l'entreprise à ce jour, démontrant un intérêt croissant pour le Swoop® Portable MR Imaging® System. Les résumés couvrent diverses applications, y compris le flux de travail aux urgences, l'implémentation en unité de soins intensifs neurologiques, la surveillance des hémorragies intracérébrales, la détection des AVC ischémiques aigus et des techniques d'imagerie avancées pour la sclérose en plaques. Les présentations mettent en évidence la polyvalence du système dans divers contextes de soins et son potentiel à transformer l'imagerie cérébrale tout en améliorant les soins aux patients.
Hyperfine (Nasdaq: HYPR) gab bekannt, dass zehn wissenschaftliche Abstracts zur Ultra-Niedrigfeldbildgebung auf dem Jahrestreffen der Radiological Society of North America (RSNA) 2024 in Chicago präsentiert werden. Dies ist die größte Anzahl von RSNA-Präsentationen des Unternehmens bis heute und zeigt das wachsende Interesse am Swoop® Portable MR Imaging® System. Die Abstracts behandeln verschiedene Anwendungen, einschließlich des Workflows in Notaufnahmen, der Implementierung in neurologischen Intensivstationen, der Überwachung intrazerebraler Blutungen, der Erkennung akuter ischämischer Schlaganfälle und fortschrittlicher Bildgebungstechniken für multiple Sklerose. Die Präsentationen heben die Vielseitigkeit des Systems in verschiedenen Pflegeumgebungen hervor und zeigen sein Potenzial zur Transformation der Gehirnbildgebung und zur Verbesserung der Patientenversorgung.
- Record number of scientific abstracts (10) to be presented at RSNA 2024, indicating growing academic interest
- Expanding clinical applications across multiple healthcare settings
- Demonstrated versatility in various medical scenarios including emergency, ICU, and stroke detection
- None.
Insights
The presentation of ten scientific abstracts at RSNA 2024 represents significant validation for Hyperfine's Swoop® portable MR technology. The research spans critical applications including acute stroke detection, hemorrhage monitoring and multiple sclerosis assessment - all key areas that could expand the system's market potential.
The abstracts demonstrate real-world clinical utility across diverse settings like emergency departments and neuro ICUs, suggesting growing acceptance among healthcare providers. Particularly noteworthy is the research on deep learning frameworks and synthetic imaging, which could enhance the technology's diagnostic capabilities and help bridge the gap with traditional high-field MRI systems.
While this scientific validation is promising for future adoption, investors should note that conference presentations alone don't guarantee commercial success. The key metrics to watch will be how this translates into actual sales and market penetration, especially given the company's current modest
The breadth of data being presented at the premier radiology meeting of 2024 illustrates the increasing relevance of portable, ultra-low-field MR brain imaging.
The Swoop® Portable MR Imaging® System (Photo: Business Wire)
“We’re excited by the scientific community’s remarkable enthusiasm for the Swoop® system,” said Dr. Edmond Knopp, Hyperfine Chief Medical Officer. “Watching our technology propel real-world applications across such diverse settings is a significant milestone for Hyperfine. We look forward to continued momentum with clinical evidence on the use of portable brain MRI and how it can transform brain imaging and enhance patient care.”
The ten abstracts highlight a broad range of clinical and technical applications across multiple sites of care, showcasing the Swoop® system’s versatility in supporting patient management. Clinical research to be presented spans workflow in both the emergency department and neuro ICU and covers clinician experience in intracerebral hemorrhage monitoring, acute ischemic stroke detection, and advanced imaging techniques for multiple sclerosis.
For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.
Conference attendees can learn more during the presentations listed below.
Name: Acute stroke detection using portable ultra low-field MRI: A multicenter outlook
Presented by: Nandor Kolos Pinter, MD
Session: Neuroradiology (Stroke: Diagnosis and Treatment) | M3-SSNR04
Date and time: Monday, December 2, 9:30–10:30 AM
Location: S406B
Name: Low-field (64mT) portable brain MRI in hospitalized and emergency department patients: Real-world experience from our first two years
Presented by: Vinu Mathew, MD
Session: Science Session (Low-Field and Mobile MRI) | T2-STCE1
Date and time: Tuesday, December 3, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Application of clinical low field mobile MRI in a large academic medical center
Presented by: Farzaneh Rahmani, MD, MPH
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Utility of low-field portable brain MRI for ruling out space-occupying lesions and hydrocephalus in patients with papilledema and other ophthalmologic signs of possible increased intracranial pressure: Preliminary experience
Presented by: Timothy Reynold Uy Lim, MD
Session: Science Session (Low-Field and Mobile MRI) | M3-STCE2
Date and time: Monday, December 2, 10:00–10:30 AM
Location: Learning Center Theater 2
Name: Efficacy of follow-up portable MRI compared to standard follow-up head CT for interval evaluation of traumatic intracranial hemorrhage
Presented by: Lauren Thompson
Session: Science Session (Low-Field and Mobile MRI) | T6-STCE2
Date and time: Tuesday, December 3, 1:30–2:00 PM
Location: Learning Center Theater 2
Name: A deep learning framework for generating synthetic low-field imaging with paired high and low-field data
Presented by: Alfredo Lucas, MS, BS
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Quantifying brain volumes and lesion burden in relation to disease duration and severity in multiple sclerosis with low-field MRI
Presented by: Alfredo Lucas, MS, BS
Session: Science Session (Low-Field and Mobile MRI) | S1-STCE1
Date and time: Sunday, December 1, 9:30–10:00 AM
Location: Learning Center Theater 1
Name: Detecting myelin loss at 0.064T using a novel myelin water imaging technique: A multiple sclerosis case study
Presented by: Shannon H. Kolind, PhD
Session: Science Session (Low-Field and Mobile MRI) | M7-STCE1
Date and time: Monday, December 2, 2:30–3:00 PM
Location: Learning Center Theater 1
Name: Implementation and reproducibility assessment of myelin-sensitive scans with mobile ultra-low field MRI
Presented by: Sharada Balaji
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Initial experience with low-field point-of-care MRI in animal stroke models
Presented by: Nandor Kolos Pinter, MD
Session: Neuroradiology Wednesday Afternoon Poster Discussions I | W5A-SPNR
Date and time: Wednesday, December 4, 12:15–12:45 PM
Location: Learning Center (Poster Session)
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119768356/en/
Media Contact
Dana Schroeder
Health+Commerce
dana@healthandcommerce.com
Investor Contact
Marissa Bych
Gilmartin Group LLC
marissa@gilmartinir.com
Source: Hyperfine, Inc.
FAQ
How many abstracts will Hyperfine (HYPR) present at RSNA 2024?
What clinical applications will be covered in Hyperfine's (HYPR) RSNA 2024 presentations?
Where will Hyperfine (HYPR) present their research at RSNA 2024?
